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Summary Using a Brown Norway rat leukaemia model (BNML), which is a realistic model of human
myelocytic leukaemia, we compared the antileukaemic activity, influence on cell cycle kinetics and effect on
normal haematopoiesis of 5 aza-2-deoxycytidine (aza-dC) and arabinofuranosyl-cytosine (ara-C). The
antileukaemic activity was evaluated by means of a survival study. For aza-dC a dose-response relationship
was demonstrated for doses up to 50mgkg-1 (3 times q 12h); a higher dose resulted in only a slight increase
in median survival time (MST). For ara-C a weak dose-response relationship was observed. At the maximum
dose of aza-dC and ara-C tested, aza-dC induced a 10-day longer survival time than ara-C, which means 2
logs more of leukaemic cell kill for aza-dC.
By means of flow cytometric analysis and a 3HTdR uptake study it was shown that aza-dC does not
influence the cell cycle kinetics in the first 24h after exposure, in contrast to ara-C which caused the
characteristic G1/S blockage and synchronization. The influence of aza-dC and ara-C on normal
haematopoiesis was evaluated with the CFU-S assay. The dose-response curve for CFU-S did not show a
significant difference in stem cell cytotoxicity between aza-dC and ara-C. In the BNML model aza-dC is a
much more effective antileukaemic agent than ara-C, while the toxic effect on normal haematopoiesis is
comparable to that of ara-C.
Arabinofuranosyl-cytosine (ara-C) is highly effective against
acute leukaemias. However, in view of the high incidence of
relapse, a considerable proportion of the leukaemic cells
apparently resists treatment with ara-C.
In a search for other antileukaemic agents, we investigated
a deoxycytidine analogue: 5 aza-2-deoxycytidine (aza-dC).
Aza-dC has shown antineoplastic activity against some
murine and human leukaemias (Momparler & Gonzales,
1978; Vesely & Czhak, 1977; Momparler et al., 1985a). In
mice inoculated with L1210 leukaemia. aza-dC was found to
be more effective than ara-C (Momparler et al., 1985b). To
acquire antileukaemic activity ara-C has to be phosphory-
lated into its nucleotide form, ara-CTP, by deoxycytidine
kinase and this metabolite is responsible for the inhibition of
DNA synthesis. Furthermore, it has been observed that very
low amounts of ara-C, which is incorporated into DNA by
replacing dC, correlate with the per cent cell kill (Major et
al., 1985). The exact mechanism behind this killing of cells is
still under investigation.
Aza-dC, which very likely follows the same intracellular
metabolic pathway as ara-C, is also an S phase-specific agent
(Chabot & Momparler, 1986). While it is assumed that ara-C
cytotoxicity is a direct result of interference with DNA
synthesis, aza-dC induces hypomethylation of DNA; the
latter has been associated with altered gene expression,
induction of differentiation and probably cell death (Jones &
Taylor, 1980; Cleusat & Christman, 1982). In mice there is a
good correlation between the inhibition of DNA methylation
produced by aza-dC and its antileukaemic activity (Wilson et
al., 1983).
In the present study we compared the antileukaemic
activity, the influence on cell cycle kinetics and the effect on
normal haematopoietic stem cells of aza-dC and ara-C in a
realistic animal model of acute myelocytic leukaemia: Brown
Norway rat myelocytic leukaemia. This model resembles
more characteristics with AML than the L1210, i.e.
myelocytic nature of the leukaemic cells, a relative slow
growth fraction and suppression of normal haematopoiesis.
Materials and methods
Chemicals
Commercially available ara-C was used; aza-dC was a gift
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from Dr P. Engel, Mack Farmazeutische Fabrik, Illertissen
(West Germany). Methyl 3H thymidine was obtained from
New England Nuclear (Boston). Aza-dC was dissolved in
phosphate-buffered saline (pH 7; 1.4mm phosphate buffer,
154mm NaCl) just before use in order to avoid degradation.
Animal model
The Brown Norway rat myelocytic leukaemia model
(BNML) has been described elsewhere (Van Bekkum &
Hagenbeek, 1977). Briefly, the leukaemia is chemically
induced in a female BN rat by means of 9,10 dimethyl 1,-2
benzanthracene. A reproducible growth pattern is obtained
upon intravenous cellular transfer of the leukaemic cells to
other BN rats. Cytologically and cytochemically the disorder
resembles human acute promyelocytic leukaemia and severe
suppression of normal haematopoiesis occurs during the
disease. In contrast to other leukaemia models the growth
fraction is relatively low: 0.60 to 0.40 in the terminal phase
of the disease. An i.v. inoculum of 107 BNML cells kills the
rat in 19-24 days. In this model a linear relationship is
observed for the number of inoculated cells from 101-107
cells and survival time (Colly et al., 1984b).
Survival study
Chemotherapy was initiated 14 days after i.v. inoculation of
107 leukaemic cells into the BN rats. Twelve groups of rats
were treated with three i.v. injections (q 12h) of ara-C (50,
75, 100, 150, 200, 500 or 1,000mgkg-1) or aza-dC (5, 25,
50, 100 or 250mgkg-1), respectively. All dead animals were
subjected to autopsy in order to judge the cause of death.
Cellular kinetics study
One i.v. injection of ara-C or aza-dC, 200mgkg-1 or
100mgkg-1 respectively, was administered to BNML rats 15
days after inoculation with 107 leukaemic cells. At the
indicated times after the ara-C or aza-dC injection, two rats
were sacrificed and bone marrow cells collected and treated
separately. A fraction of these cells was prepared for cell
cycle phase analysis by means of flow cytometry and DNA
synthesis studies by means of 3HTdR uptake determination.
For flow cytometric analysis the nuclei of the bone
marrow cells (106 cellsml-1) were stained with the fluores-
cent dye propidium iodide. The stained cells were subjected
to flow cytometry (FACS IV cell sorter, Becton and
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Dickinson, Sunnyvale, Ca). The DNA histograms were
analyzed with a Minc II (Digital Maynard, Ma) (Dean et al.,
1982). For 3HTdR uptake determination the bone marrow
cells were resuspended in RPMI 1640 containing 5% foetal
calf serum (Gibco) in a concentration of 2 x I05 cellsml-1.
These cell suspensions were incubated with 1 MCi [3H] methyl
thymidine (20Cimmol-1) for 1 h at 37°C in 5% CO2. The
cells were trapped on GF/C glass fibre filters (2.4cm diam.)
and washed with sterile 0.9% NaCl, cold 5% trichloroacetic
acid and 96% ethanol. The disc was dried and placed in
scintillation fluid to determine the amount of radioactivity
incorporated into DNA.
Colony forming unit-spleen assay (CFU-S)
This method of quantifying the number of pluripotent
haematopoietic stem cells (HSC) was first described by Till
and McCulloch (1961) for mouse bone marrow cells, and
later on modified for the rat (Van Bekkum, 1977). CFU-S
were determined by pooling femoral bone marrow cells
drawn from 3 normal rats at different time intervals after
one i.v. injection of aza-dC or at 4h after different doses of
aza-dC. A fraction of these cells was injected into F1 hybrids
of C57 BL/L, Rij xC3H/LW Rij mice, which had undergone
9.25Gy total body irradiation.
Nine days after injection of the rat bone marrow cells, the
mice were sacrificed and the spleens were harvested and fixed
in Tellyesniczky's solution (ethanol 70%, formaldehyde 36%,
acetic acid 100%, 20:1:1); the macroscopically visible
colonies could easily be counted. A linear relationship was
found between the number of cells injected and the number
of spleen colonies formed (Van Bekkum, 1977).
Results
Effect of aza-dC and ara-C on survival of leukaemic rats
Figure 1 shows the dose-response relationship, as indicated
by the increase in median survival time (MST), for both
drugs for BNML rats and non-treated leukaemic control
animals. The increase in MST can be considered as a
parameter of the antileukaemic effect. All animals died of
progressive leukaemia, except 2 rats in the ara-C group, who
died within 12h after the first ara-C injection. These animals
are presumed to be cases of toxic death and are therefore
excluded from the data in Figure 1. For aza-dC, MST
increased in a dose-dependent fashion for dosages up to
50mgkg-1; higher dosages did not produce a significant
improvement in MST. The dose response relationship for
low dose ara-C did not. become clear in this study; at
dosages exceeding 200mgkg-1 a slight increase in MST was
observed. The MST curve for the aza-dC group is higher
than that found for the ara-C group. At the highest dosages
tested the increase in MST for ara-C was + 14 days and for
aza-dC +24 days (P<0.001 t-test).
-J
Z so z 50-
m
r,
o40-
, X
a) -a r
- 30-
m
g 0-
Cl)
50
40
30
20
~~*- +-
Cellular kinetics of aza-dC and ara-C
Figure 2 shows the effects of an i.v. injection of ara-C or
aza-dC on DNA synthesis in leukaemic bone marrow cells.
In vitro 3H-thymidine incorporation into bone marrow cells
dropped sharply after an ara-C injection to -50% of the
initial value, followed by a sudden increase to - 3 x the
initial value 16h after the injection and normalization at the
end of the study.
In contrast to these observations, injection of aza-dC
caused no changes in DNA synthesis; the results were
comparable to those found for the control group.
The effects of ara-C and aza-dC on the percentage cells in
S phase are shown in Figure 3. In this experiment the values
for the percentage cells in S phase after ara-C are similar to
those observed in previous studies (Colly et al., 1984a) and
show the pattern of synchronization of leukaemic cells,
which is reflected in the accumulation of 50% cells in S
phase. As in the 3HTdR uptake study no changes in the
percentage cells in S phase occurred during the first 24h
after the aza-dC injection.
Effect of ara-C and aza-dC on CFU-S
Figure 4 shows the toxic effects of various dosages of ara-C
and aza-dC on haematopoietic stem cells, as indicated by a
decrease in the number of rat bone marrow colonies growing
in the spleens of irradiated mice.
Even at the lowest dose of aza-dC (5mgkg-1) tested, the
number of colonies dropped to -60% of the initial value, a
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Figure 2 3HTdR uptake studies of leukaemic bone marrow cells
after injection of aza-dC (l00mgkg-I rapid i.v. * 0),
ara-C (200mgkg rapid i.v. A A) or no drug (leukaemic
controls O OL) into BNML rats. At the indicated hours
after the injection 2 rats in each group were sacrificed and the
leukaemic bone marrow cells were incubated separately with 3H
thymidine.
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Figure 1 Dose-response relationship between increasing dosages
of aza-dC or ara-C (each dose is given 3 times q 12 h i.v.) and
survival time after inoculation of 107 leukaemic cells.
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Figure 3 Comparison of percentage cells in S phase after
injecting BNML rats with ara-C (200mgkg-1): A A or
aza-dC (100mgkg-1): 0 0. The leukaemic cells were
obtained from the animals described in Figure 2.
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plateau that persisted with increasing dosages. A similar
pattern has been described for ara-C, although the plateau
stabilized at +75% of the initial value (Colly & Van
Bekkum, 1982). This difference between aza-dC and ara-C,
however, was not significant (P=0.05, Mann-Whitney). The
duration of suppression of the number of haematopoietic
stem cells (CFU-S) produced by an injection of aza-dC
(5mgkg-1) is shown in Figure 5. The plateau of 60% was
still evident 12h after injection.
Discussion
In previous studies the effect of aza-dC on acute leukaemia
in mice and in vitro was investigated. An important question
about this deoxycytidine analogue is whether or not this
agent has advantages over ara-C. Since experience with the
Brown Norway rat leukaemia model indicated that ara-C is
an effective drug with moderate toxic side effects, this animal
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Figure 4 Dose-response relationship between increasing aza-dC
doses and the number of CFU-S per 105 nucleated bone marrow
cells. Different symbols are the mean for different experiments
and represent mean + s.e. Inlay: comparable study for ara-C
(Colly and Van Bekkum, 1982).
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Figure 5 Changes in the number of CFU-S per 105 nucleated
bone marrow cells at different time intervals after one aza-dC
injection of 5 mgkg-1. Different symbols are the mean for
different experiments and represent mean+s.e.
model is very suitable for such a study; moreover it
simulates in a more precise way the characteristics of human
leukaemia (Colly et al., 1984b, 1986).
Ara-C, the most active antileukaemic drug against human
leukaemia, has been shown to increase the survival time for
leukaemic Brown Norway rats in a weak dose-related
fashion. A 5-fold increase in the dosage of 200mgkg-1
resulted in only a slight prolongation of survival time in this
model. Since 200mgkg-1 body weight for a rat equals
1 gm-2 for man, this observation might indicate that the use
of higher dosages of ara-C does not contribute to its
antileukaemic effectiveness in man. For dosages up to
50mgkg-1 aza-dC, survival time increases in a dose-related
fashion; however, no further increase in MST was observed
at higher dosages. The MST at this plateau level is however
much longer than the MST found for rats treated with high-
dose ara-C. Since in this model a linear relationship exists
between the number of cells transplanted and survival of the
recipients (Colly et al., 1984b), the difference in the MST
induced by each agent can be translated into the leukaemic
cell kill. The increase in survival of 8-10 days induced by
aza-dC means that 3 i.v. injections of the latter agent kills
two logs more cells than 3 injections of ara-C (Colly et al.,
1984b).
In addition to its antileukaemic effect, the unique effects
of ara-C on cell cycle kinetics (such as the G1/S blockade
and cell recruitment and synchronization) have been studied
in the rat model (Colly et al., 1984a). In this model manipu-
lation of these phenomena led to optimal treatment
programs. However, clinical application of this knowledge
has been hampered by the heterogeneity among human
leukaemias (Colly et al., submitted). A comparison of the
effects on the cell cycles of ara-C and aza-dC, as illustrated
in Figures 3 and 4, reveals that the differences are striking.
No alterations in cell cycle progression could be observed in
the first 24h after an injection of aza-dC. This is compatible
with our observation in leukaemic cell lines, that growth
inhibition and cytotoxic effects became evident 2 cell
cycles after incubation with aza-dC. Ultimately aza-dC
induces cytotoxicity, as has been proven with colony
formation assays (Momparler & Goodman, 1977).
It has been postulated that ara-C inhibits its own cell toxic
actions by the G1/S blockade: since the cells accumulate at
the G1/S boundary, they do not enter S phase and are thus
protected against cytotoxicity. Delay of cell cycle progression
at G1/S could not be demonstrated for aza-dC, which might
explain the greater antileukaemic activity observed.
Extreme haematological toxicity can limit the effectiveness
of a cytostatic drug. Stem cell toxicity in man cannot be
studied easily, but in the rat model it can be assessed by
means of the CFU-S assay. Our study of ara-C and aza-dC
showed that, in contrast to the dose-related antileukaemic
activity, the maximum number of haematopoietic stem cells
is already killed at relatively low dosages. Although there is
a small difference between the two drugs in this respect, it is
not significant. The latter observation combined with more
effective antitumour effect of aza-dC implicates that aza-dC
is a more effective antileukaemic agent than ara-C.
The difference between stem cell toxicity and anti-
leukaemic effect favours treatment with high dosages of
these agents, because the dose which causes maximal
leukaemic cell kill is not more toxic for stem cells.
During the first 12h after low dose aza-dC treatment
(5mgkg-1) no recovery of initial stem cell values is
observed. Longer follow up studies are required to study
recovery from the toxic effect of aza-dC on stem cells. In
summary it can be concluded that because of its increased
antileukaemic activity, while the haematologic toxicity is
comparable to ara-C, aza-dC might be very interesting
clinically. In addition scientifically the many differences in
biochemical properties with respect to ara-C also make it a
fascinating agent.
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